Gossamer Bio, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report covers events occurring on June 25, 2025, specifically the Company's 2025 Annual Meeting of Stockholders. The filing details the outcomes of shareholder votes regarding director elections, auditor ratification, executive compensation, and the approval of an amended equity incentive plan.
Key Financial Metrics
This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. No financial statements or metrics are included in this document.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders at the Annual Meeting:
- Director Elections: Three Class I directors were re-elected for a three-year term expiring in 2028.
- Thomas Daniel, M.D.: 104,358,112 For; 25,242,954 Withheld.
- Sandra Milligan, M.D., J.D.: 104,165,685 For; 25,435,381 Withheld.
- Steven Nathan, M.D.: 114,441,599 For; 15,159,467 Withheld.
- Auditor Ratification: Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Result: 176,512,996 For; 98,411 Against; 105,847 Abstain.
- Executive Compensation (Say-on-Pay): Advisory approval of named executive officer compensation.
- Result: 125,358,485 For; 3,769,651 Against; 472,930 Abstain.
- Equity Plan Approval: The Amended and Restated 2019 Incentive Award Plan was approved.
- Result: 87,795,419 For; 41,469,393 Against; 336,254 Abstain.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, operational outlook, or specific risk factors. The document strictly reports the procedural outcomes of the Annual Meeting. The approval of the Amended and Restated 2019 Plan allows the Company to continue granting equity awards under the terms described in the 2025 Proxy Statement.
Key Facts for Investor Verification
- Verify the specific terms of the Amended and Restated 2019 Incentive Award Plan in the 2025 Proxy Statement (Schedule 14A) filed on April 29, 2025, as this plan received significant opposition (approx. 32% against).
- Note the high number of broker non-votes (47,116,188) on director elections and the equity plan, indicating shares held in street name where brokers lacked discretionary voting power.
- Confirm the re-election of the Class I directors, noting that while all were elected, there were substantial "withheld" votes for Thomas Daniel and Sandra Milligan.
- Review the 2025 Proxy Statement for detailed compensation data, as this 8-K only reports the vote tally for the advisory compensation proposal.